PATIENTS
Benefiting from the most efficient or adapted therapy to cure from disease and/or to be cured with the best quality of life during treatment
ACOBIOM
Providing innovative and non-invasive Blood-based In Vitro Diagnostic to predict patient response to a certain therapy
CLINICS & HOSPITALS
Making a diagnosis, treating, providing medical follow-up with the objective to personalize patient’s medical care in taking into account individual differences
GemciTest ®
The first diagnostic to predict the patient response in pancreatic cancer treatment
PANCREATIC CANCER
A rare and “silent” disease with no symptom early on, difficult to diagnose and cure.
DIAGNOSTIC
A blood-based molecular test (RUO diagnostic) to predict patient’s therapeutic response
GEMCITABINE
The less toxic and expensive chemotherapy in pancreatic cancer treatment
BLOOD RNA-SIGNATURE
A combination of biomarkers to identify patients most likely to benefit from gemcitabine
Prescribing the right treatment to the right patient requires funds.
To obtain more information about ACOBIOM’s developments, please visit the “Investors” page
Our Expertises
Acobiom is an innovative biotechnology company specialized in the discovery of new biomarkers and in the development of innovative diagnostics.
BIOMARKERS
Analyses of biological phenotypes; investigation of gene expression changes; Identification & validation of acid nucleic (DNA, RNA, miRNA, small RNA, coding & non coding RNA) biomarkers based on Sequencing/NGS & PCR technologies.
BIOINFORMATICS
Treatments & analyses of sequencing/omics big data through a proprietary suite of Bioinformatic and Biostatistic tools; Development of a 21,000 Human RNA-Seq database, in-silico investigations through public & proprietary databases.
PRECISION MEDICINE
Biomarkers and diagnostics “to optimize a specific preventive, diagnostic or therapeutic intervention in a given subpopulation of patients, which would most likely to benefit from it”.
GENOMICS
A unique scientific and technical expertise associated with 20-year experience in genomics & transcriptomics, in sequencing/NGS & PCR technologies, in performing RNA-Seq / ChIP-seq analyses, and PCR / qPCR / qRT-PCR experiences.
Latest News
ACOBIOM and Montpellier University Hospital: a partnership on heart failure (MeDIAGSTOLE project)
The MeDIAGSTOLE project aims to develop diagnostic and prognostic tools for left ventricular heart
failure with preserved ejection fraction (HF/pEF), a pathology that is difficult to diagnose and clinically
manage in the absence of targeted treatment. In this context, the University Hospital of Montpellier
and ACOBIOM decided to collaborate in order to identify biomarkers associated with this pathology,
and thus to participate in the implementation of personalized medicine for patients suffering from
this type of heart failure (HF/pEF).
RNA-Seq, ACOBIOM’s expertise to perform RNA Analysis by sequencing
Unlike DNA, which is constituted at birth and changes little over the course of Life, RNA is constantly evolving, reflecting the general state of health of the cell, organ and organism to which it belongs. RNA analysis (or gene expression analysis) is a particularly relevant approach to identify the biological markers (biomarkers) or the molecular targets associated to a biological process, a physio-pathological event, as the onset or the progression of a disease, the effects or the response to a drug or a treatment. RNA-Seq, a high throughput approach to perform RNA analysis by sequencing, become the standard technology to identify transcripts in cells and to quantify the associated expressed genes.
Read more
ACOBIOM presents GEMCITEST®
GEMCITEST® is a molecular diagnostic that uses blood samples to identify pancreatic cancer patients most likely to benefit from first-line gemcitabine treatment.
Read moreABOUT ACOBIOM
Since its foundation, Acobiom has always been at the forefront of Medical Innovation.
Acobiom was founded by Didier Ritter and Dr David Piquemal under the name « Skuldtech » to promote the gene expression profile (transcriptome) approach with the objective to discover RNA biomarkers, to develop diagnostics, and to improve the patient’s medical care.
FOR MORE INFORMATION
